Nephron Corporation is a medicare approved dialysis facility center in Monroe, Georgia and it has 21 dialysis stations. It is located in Walton county at 710 Breedlove Dr, Monroe, GA, 30655. You can reach out to the office of Nephron Corporation at (678) 635-7211. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Nephron Corporation has the following ownership type - Non-Profit. It was first certified by medicare in December, 2008. The medicare id for this facility is 112804 and it accepts patients under medicare ESRD program.
| Name | Nephron Corporation |
|---|---|
| Location | 710 Breedlove Dr, Monroe, Georgia |
| No. of Dialysis Stations | 21 |
| Medicare ID | 112804 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 710 Breedlove Dr, Monroe, Georgia, 30655 | |
| (678) 635-7211 | |
News Archive
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.
A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European "DYANA" (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm's Dynaplasty technology in Europe.
› Verified 7 days ago
| NPI Number | 1104930023 |
| Organization Name | Walton Dialysis Center |
| Doing Business As | Nephron Corporation |
| Address | 710 Breedlove Dr Monroe, Georgia, 30655 |
| Phone Number | (770) 962-1231 |
News Archive
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.
A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European "DYANA" (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm's Dynaplasty technology in Europe.
› Verified 7 days ago
| Dialysis patients with Hemoglobin data | 2 |
News Archive
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.
A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European "DYANA" (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm's Dynaplasty technology in Europe.
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 18 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 167 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.
A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European "DYANA" (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm's Dynaplasty technology in Europe.
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Nephron Corporation with elevated calcium levels.
| Patients with hypercalcemia | 18 |
| Hypercalcemia patient months | 167 |
| Patients with Serumphosphor | 19 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 29 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.
A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European "DYANA" (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm's Dynaplasty technology in Europe.
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 15 |
| Patient months included in arterial venous fistula and catheter summaries | 116 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 84 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 5 |
News Archive
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.
A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European "DYANA" (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm's Dynaplasty technology in Europe.
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 16 |
| Hospitalization Rate in facility | 107.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 536.8 |
| Hospitalization Rate: Lower Confidence Limit | 24.3 |
News Archive
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.
A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European "DYANA" (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm's Dynaplasty technology in Europe.
› Verified 7 days ago